Indoco Remedies
Indoco Remedies Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
The order book for international formulations business to Europe and US stands at about INR180 crores, indicating expected sales recovery. Short-term (next two quarters) earnings are expected to remain impacted due to US FDA warning letter issues and supply constraints from the sterile plant.
From Indoco Remedies's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The order book for international formulations business to Europe and US stands at about INR180 crores, indicating expected sales recovery.
- Europe business is expected to drive growth with an anticipated margin of close to 15% starting FY '26.
- US business recovery is delayed due to FDA remediation; scale-up expected once compliance issues resolve.
- Domestic business shows steady growth with top brands like Cyclopam growing over 20% in prescriptions.
- New product launches and strategic partnerships (e.g., with Clarity Pharma UK for 18 SKUs over 18 months) support revenue growth.
2 more points from Indoco Remedies's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Indoco Remedies said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Indoco Remedies has undertaken significant capex of around INR 400 crores in the past 2 years, mainly for refurbishment and capacity expansion.
- Key investments include:
- Setting up a new unit at Auric for manufacturing cosmetic toothpaste (OTC toothpaste).
- Capacity increase for API production beyond the old site at Patalganga.
- Upgrading equipment to improve efficiency at the solid oral manufacturing site.
- In the current year, about INR 200 crores has been incurred, covering new machines, upgrades, refurbishment, and some advances.
- Equipment upgrades are aligned with digital initiatives to enable data collection and AI/ML applications for predictive quality and efficiency improvements.
2 more points from Indoco Remedies's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Indoco Remedies said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The current order book for the international formulations business to Europe and the US stands at approximately INR 180 crores.
- This order book reflects the demand side strength despite supply-side challenges.
- The company has faced a significant sales drop in the regulated markets due to remediation and supply disruptions but holds this order backlog as a positive indicator.
- There is an expectation of recovery in supply and a return to earlier performance levels in markets outside the US starting from FY '26 onwards.
2 more points from Indoco Remedies's call on order book
Pro opens every point from 15K+ earnings calls
Indoco Remedies — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹476 Cr, net loss ₹24 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Indoco Remedies Ltd's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- NGL Fine Chem Ltd (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…
- Fermenta Biotech Ltd (Q3 FY25)
Q3-FY25 consolidated operational revenue: INR 1,565 Mn, up 58.1% YoY (Page 12) . Key concall takeaways from Fermenta Biotech Ltd's Q3 FY25 earnings call — and…
- Amrutanjan Health Care Ltd (Q3 FY25)
122.75 Cr, up 4.92% YoY (Q3 FY24: Rs. Key concall takeaways from Amrutanjan Health Care Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
Arthneeti Pro · Annual
Indoco Remedies and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Indoco Remedies Q3 FY25 results?
The order book for international formulations business to Europe and US stands at about INR180 crores, indicating expected sales recovery. Short-term (next two quarters) earnings are expected to remain impacted due to US FDA warning letter issues and supply constraints from the sterile plant.
What is Indoco Remedies share price analysis?
Indoco Remedies currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹2,026 Cr. Investors should review the full earnings analysis for detailed insights.
Is Indoco Remedies planning capital expenditure?
Indoco Remedies has undertaken significant capex of around INR 400 crores in the past 2 years, mainly for refurbishment and capacity expansion.
Keep Indoco Remedies on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.